Physician profile
Kyle Sandberg
NPI 1699036186
$5,317.52
in general payments reported to CMS, 2019-2025
14 companies · $826 in 2025
The $826 reported for 2025 was more than what 88% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $467 · 2020: $87.78 · 2021: $1,283 · 2022: $134 · 2023: $717 · 2024: $1,802 · 2025: $826.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,220 · Consulting Fee: $900 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $225.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,220.37 |
| Consulting Fee | $900.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $225.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tarsus Pharmaceuticals, INC. | $1,903.86 | 2024-2025 | Xdemvy |
| Allergan, INC. | $1,003.01 | 2021 | |
| Biotissue Holdings INC. | $489.81 | 2020-2024 | |
| Abbvie INC. | $359.84 | 2023-2024 | Durysta, Vuity |
| Coopervision INC. | $316.15 | 2019-2024 | Clariti Contact Lens, Misight Contact Lens |
| Dompe US, INC. | $303.07 | 2024-2025 | Oxervate |
| Sun Pharmaceutical Industries INC. | $185.48 | 2019-2025 | Cequa |
| Alcon Vision LLC | $159.71 | 2019-2021 | |
| Johnson & Johnson Vision Care, INC. | $158.72 | 2019-2021 | |
| Bausch & Lomb Americas INC. | $142.86 | 2025 | Xiidra, Miebo |
| Novartis Pharmaceuticals Corporation | $130.12 | 2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $115.90 | 2019 | |
| Oyster Point Pharma, INC. | $31.86 | 2022 | |
| Glaukos Corporation | $17.13 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kyle Sandberg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.